Claims for Patent: 8,915,877

Summary for Patent: 8,915,877

Title:	Glaucoma drainage device and uses thereof
Abstract:	In one aspect, the present invention provides an implant device for use in an eye with elevated intraocular pressure or glaucoma. In another aspect, the present invention provides a method for lowering intraocular pressure and/or treating a condition associated with elevated intraocular pressure using the implant device of the present invention.
Inventor(s):	Cunningham, Jr.; Emmett T. (Hillsborough, CA)
Assignee:
Application Number:	13/272,062
Patent Claims:	1. A device for use in an eye with elevated intraocular pressure or glaucoma, the device comprising a tubular body portion comprising a plurality of lumens, wherein each lumen terminates at an inlet section at a first end of the tubular body and at an outlet section at a second end of the tubular body, and wherein one or more of the plurality of lumens are selectively controllable between an open position and closed position, wherein when any of said lumens are open, said device is configured to divert intraocular fluid from a vitreous cavity to a subconjunctival space; wherein the inlet section comprises a first flange-like structure or first securing structure in close apposition to an intraocular surface; and wherein the outlet section is in fluid communication with the inlet section and comprises a second flange-like structure or second securing structure that is configured to rest on the sclera. 2. The device of claim 1, wherein the tubular body portion has an 18 gauge or less external size. 3. The device of claim 1, wherein the tubular body portion is adapted and configured for placement in isolation at a pars plana to provide for direct intraocular fluid flow from the vitreous cavity to the subconjunctival space. 4. The device of claim 1, wherein the tubular body portion is adapted and configured for placement in direct or indirect connection with one or more devices in the subconjunctival space that are intended to enhance and/or direct intraocular fluid flow from the vitreous cavity to the subconjunctival space. 5. The device of claim 1, wherein the inlet section comprises a clogging minimizing structure that minimizes clogging of the fluid communication at the inlet section by formed vitreous, blood, intraocular tissues, or scar formation, wherein the clogging minimization structure comprises multiple ports in fluid communication with each of the lumens. 6. The device of claim 1, wherein at least one lumen comprises a flow regulating member. 7. The device of claim 6, wherein the flow regulating member is selected from the group consisting of a plurality of nanotubes, a plurality of capillary tubes, a plurality of collimated passages and combinations thereof. 8. The device of claim 6, wherein the flow regulating member comprises a biological mechanoprotein used to regulate fluid flow. 9. The device of claim 6, wherein the flow regulating member is a membrane or a micromechanical valve. 10. The device of claim 1, wherein said lumens are selectively openable in situ. 11. The device of claim 10, wherein each of the lumens is initially closed and irreversibly openable. 12. The device of claim 11, wherein at least one of the irreversibly openable lumens comprises a soluble barrier that is initially non-patent and over time due to the time-dependent erosion, dissolution or decomposition of the soluble barrier becomes patent. 13. The device of claim 11, wherein at least one of the irreversibly openable lumens comprises a barrier such as a membrane or plug that is initially non-patent and selectively opened using an external laser. 14. The device of claim 11, wherein at least one of the irreversibly openable lumens comprises a barrier such as a membrane or plug that is initially non-patent and selectively opened using an external mechanical probe. 15. The device of claim 10, wherein each of the lumens has a size that is different from the other lumen. 16. The device of claim 15, wherein the size is between about 20 and 50 gauge. 17. The device of claim 10, wherein each of the lumens is labeled so as to be differentiated from the other lumen. 18. The device of claim 17, wherein at least one lumen is labeled by color. 19. The device of claim 1, wherein the inlet section comprises an anti-clogging shaped structure selected from the group consisting of a spiral, a screw, or a helix-shaped structure and combinations thereof. 20. The device of claim 1, wherein the inlet section comprises a structure for minimizing clogging selected from the group consisting of a filter membrane, surface corrugations, a surrounded cage structure, surface ridges, multiple ports, multiple perforations, and combinations thereof. 21. The device of claim 1, wherein the outlet section comprises the second flange-like structure which is larger than the tubular body portion. 22. The device of claim 1, wherein the inlet section comprises the first flange-like structure which is larger than the tubular body portion. 23. The device of claim 1, wherein the tubular body portion comprises a securing structure and wherein the securing structure is selected from the group consisting of a tissue adhesive, one or more barbs, a threading mechanism, a structure for suture placement, and combinations thereof. 24. The device of claim 1, wherein the device is made of a biocompatible material selected from the group consisting of titanium, stainless steel, silicone, polyurethane, polylactic acid, polylactic alcohol, polyvinyl pyrolidone, collagen, heparinized collagen, polytetrafluoroethylene, expanded polytetrafluoroethylene, fluorinated polymer, fluorinated elastomer, flexible fused silica, polyolefin, polyester, polysilicon, polyamide, parylene, and combinations thereof. 25. The device of claim 1, wherein the device has a drug-eluting coating. 26. The device of claim 25, wherein the drug-eluting coating comprises an anti-inflammatory agent. 27. The device of claim 26, wherein the anti-inflammatory agent is selected from the group consisting of corticosteroids, immunosuppressive agents, non-steroidal anti-inflammatory drugs, anti-inflammatory proteins, peptides, or nucleic acids, and combinations thereof. 28. The device of claim 25, wherein the drug-eluting coating comprises an anti-proliferative agent. 29. The device of claim 28, wherein the anti-proliferative is selected from the group consisting of a corticosteroid, an immunosuppressive agent, mitomycin, 5-fluorouracil, heparin, anti-proliferative proteins, peptides, or nucleic acids and combinations thereof. 30. The device of claim 25, wherein the drug-eluting coating comprises an anti-microbial agent. 31. The device of claim 25, wherein the drug-eluting coating comprises an intraocular pressure lowering agent. 32. The device of claim 25, wherein the drug-eluting coating comprises a vitreolytic agent. 33. The device of claim 32, wherein the vitreolytic agent is selected from the group consisting of a dispase, urea, collagenase, hyaluronidase, plasmin, microplasmin, chondroitinase, a protease, and combinations thereof. 34. A method for lowering intraocular pressure, comprising: introducing into an eye a device comprising a tubular body portion comprising a plurality of lumens, wherein each lumen terminates at an inlet section at a first end of the tubular body and at an outlet section at a second end of the tubular body, wherein one or more of the plurality of lumens are selectively controllable between an open position and closed position, wherein when any of said lumens are open, said device is configured to divert intraocular fluid from a vitreous cavity to a subconjunctival space, wherein the inlet section comprises a first flange-like structure or first securing structure in close apposition to an intraocular surface, and wherein the outlet section is in fluid communication with the inlet section and comprises a second flange-like structure or second securing structure that is configured to rest on the sclera; and diverting intraocular fluid from the vitreous cavity to the subconjunctival space at pars plana. 35. The method of claim 34, wherein the device is a self-contained transmural shunt device. 36. The method of claim 34, wherein the device resides entirely within the pars plana. 37. The method of claim 34, further comprising an eye surgery trabeculectomy.

Details for Patent 8,915,877

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	05/05/2004		2030-10-12
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	12/02/2004		2030-10-12
Amphastar Pharmaceuticals, Inc.	AMPHADASE	hyaluronidase	Injection	021665	10/26/2004		2030-10-12
Akorn, Inc.	HYDASE	hyaluronidase	Injection	021716	10/25/2005		2030-10-12